学习长期和短期的依赖性,以改善药物标结合亲和力预测,使用变压器和边缘收缩聚合
Min Gao1, Shaohua Jiang1, Weibin Ding1
1College of Information Science and Engineering, Hunan Normal University, Changsha, P. R. China.
Journal of bioinformatics and computational biology
|April 3, 2024
概括
ETransDTA是一种新的深度学习模型,通过整合全球和本地蛋白质特征,准确地预测药物向亲和力. 这一进步通过提高结合亲和力预测的精度来增强药物发现.
科学领域:
- 计算生物学是一种计算生物学.
- 药物发现 药物发现
- 生物信息学是一种生物信息学.
背景情况:
- 准确的药物向亲和力 (DTA) 预测对于药物发现至关重要.
- 现有的深度学习方法难以捕捉全球蛋白质特征.
研究的目的:
- 开发一个新的模型,ETransDTA,用于增强DTA预测.
- 为了同时提取目标蛋白质的全球和本地特征.
主要方法:
- ETransDTA结合了卷积层和变压器来进行特征提取.
- 图形聚合机制集成到拓自适应图形卷积网络 (TAGCN) 中,用于化学化合物表示.
- 该模型利用堆叠卷积神经网络 (CNN) 的查询,密钥和值来实现集成的上下文.
主要成果:
- 在戴维斯和KIBA数据集上,ETransDTA的表现优于基线方法.
- 在KIBA数据集上实现了0.125的平均平方误差 (MSE),改善了0.6%.
- 证明了本地和全球蛋白质背景的增强整合,以提高DTA预测准确度.
结论:
- ETransDTA在DTA预测准确度方面取得了重大进展.
- 该模型捕捉全球和本地特征的能力改善了药物发现管道.
- ETransDTA提供了一个更强大的工具来识别潜在的候选药物.
更多相关视频
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024
1.8K
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
5.0K
相关概念视频
Conserved Binding Sites
4.2K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.2K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
